NCT01386580 / 2011-001119-30: An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. |
|
|
| Completed | 1/2 | 84 | US, Europe | 2B3-101, Glutathione pegylated liposomal doxorubicin hydrochloride, Trastuzumab, Herceptin, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks | BBB-Therapeutics B.V. | Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma | 12/14 | 12/14 | | |
